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MEETING PROCEEDINGSHighlights from American Heart Association Annual Scientific
Sessions 2009: Orlando, Florida, November 14–18, 2009Akshay Desai, MD, MPH, and Frederic S. Resnic, MD, MScThe annual scientific sessions of the American Heart Asso-
ciation were held November 14–18, 2009, in Orlando, Flor-
ida. This internationally attended meeting was the venue for
the release of new clinical trial data as well as an ongoing
comprehensive review of many subjects of interest to cardio-
vascular specialists throughout the world. We provide here
a brief overview of some of the most innovative and impor-
tant developments from the American College of Cardiology
scientific sessions.THERAPIES FOR HEART FAILURE
Continuous-Flow Ventricular Assist Devices as
Destination Therapy
The results of the landmark REMATCH trial (Random-
ized Evaluation of Mechanical Assistance for the Treatment
of Congestive Heart Failure), released in 2001, demonstrated
a significant survival advantage in transplant-ineligible pa-
tients randomized to use of a pulsatile left ventricular assist
device (LVAD) as ‘‘destination therapy’’ relative to those
managed with optimal medical therapy.1 However, 2-year
survivals remain suboptimal despite LVAD support (23%
vs 8% with medical therapy), and the broader application
of LVAD therapy to the population with advanced heart
failure has been limited by device size, adverse events (in-
cluding thromboembolism and infection), and durability.
Second-generation, nonpulsatile VAD designs offer poten-
tial advantages over pulsatile VADs with regard to size,
patient comfort, and durability and have proven effective as
a therapeutic bridge to cardiac transplantation.2 Slaughter
and colleagues3 presented the results of a prospective,
randomized comparison of continuous-flow versus
pulsatile-flow LVADs in destination therapy, which included
200 transplant-ineligible patients randomly assigned in a 2:1
ratio to receive either a continuous-flow Thoratec HeartMate
II (134 patients) (Thoratec Corporation, Pleasanton, Calif) or
a pulsatile-flow Thoratec HeartMate XVE device (66 pa-
tients). Treatment with the continuous-flow device was asso-
ciated with a significant improvement in the composite end
point of survival at 2 years without disabling stroke or reop-
eration to replace the device (46% vs 11%; P<.001), driven
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also significantly improved in the continuous-flow group
(58% vs 24%; P ¼ .008), as were the rates of major adverse
events including device-related infection, right heart failure,
and rehospitalization for heart failure. No advantage was
seen with regard to stroke (17% vs 14%; P> .05).3 These
findings underscore the superiority of continuous-flow
LVADs over pulsatile-flow LVADs for the management of
heart failure in transplant-ineligible patients.
Treatment of Iron Deficiency to Improve Symptoms
in Patients With Heart Failure
Patients with heart failure may be prone to iron deficiency
owing to impaired dietary absorption, depleted iron stores,
or defective iron mobilization. Anker and associates4 pre-
sented the results of the FAIR-HF trial (Ferinject Assess-
ment in Patients with Iron Deficiency and Chronic Heart
Failure) with the goal of assessing the impact of intravenous
iron treatment on patient-reported symptoms in heart failure.
A total of 459 patients with New York Heart Association
(NYHA) class II heart failure and a left ventricular ejection
fraction of 40% or less or NYHA class III heart failure and
an ejection fraction of 45% or less, hemoglobin level be-
tween 95 and 135 g/L, and iron deficiency (as assessed by
serum ferritin levels) were randomly assigned in a 2:1 ratio
to treatment with 200 mg of intravenous ferric carboxymal-
tose or placebo. At 24 weeks, 50% of patients in the iron-
repletion group and 28% of controls reported that they
were much or moderately improved on the Patient Global
Assessment survey (odds ratio 2.51; P< .001). Similarly,
47% of iron-treated patients were in NYHA class I or II
at week 24, as compared with 30% of patients assigned to
placebo (odds ratio for improvement by one class, 2.40;
P< .001). Significant improvements were also noted in
pre-specified secondary end points including 6-minute
walk distance and health-related quality of life. Of note, ben-
efits accrued in patients with and without anemia, suggesting
that correction of iron deficiency, rather than correction of
anemia, may have been responsible.
PHARMACOLOGYAFTER CARDIAC SURGERY
No Clinical Benefit of Clopidogrel on Progression of
Saphenous Vein Graft (SVG) Disease
SVG patency rates have been estimated to be approxi-
mately 85% at 1 year5 and 50% at 10 years.6 The CASCADE
investigators (Cardiac Arrest in Seattle: Conventional Versus
Amiodarone Drug Evaluation) undertook a randomized study
to determine the effect of clopidogrel 75 mg relative togery c April 2010
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VAD ¼ ventricular assist deviceplacebo on vein graft intimal area at 1 year (assessed by in-
travascular ultrasound) in 112 aspirin-treated patients. SVG
patency rates at 1 year were high in both arms of the study
(94.3% for aspirinþclopidogrel vs 93.2% for aspirinþpla-
cebo; P¼ .78). Among the 90 patients who received follow-
up intravascular ultrasound assessment, those assigned to
clopidogrel had less SVG intimal area than those assigned
to aspirin, but this difference did not achieve statistical sig-
nificance (4.1 mm2 vs 4.9 mm2, reduction 14.8%; P ¼ .21).
No statistical difference in major bleeding was seen between
the 2 arms.
No Benefit of Diclofenac on Persistent Pericardial
Effusion After Cardiac Surgery
Pericardial effusion is a common complication of cardiac
surgery. Although most effusions resolve spontaneously,
postoperative effusions occasionally progress to tamponade
and potentially life-threatening compromise of cardiovascular
function. The POPE study (Post-Operative Pericardial Effu-
sion) randomized 196 patients with grade 2 to 4 pericardial
effusions 1 week after cardiac surgery to treatment with the
nonsteroidal anti-inflammatory drug diclofenac (50 mg bid)
or placebo. No difference was observed between the 2 treat-
ment arms in the primary end point of decrement in pericardial
effusion grade at 14days or in the incidence of late tamponade.
Of note, however, there was a 10% incidence of progression
to tamponade requiring drainage between postoperative days
20 and 30, highlighting a need to explore alternative surveil-
lance and management strategies for this problem.
ANTIOCOAGULATION WITH DABIGATRAN IN
ATRIAL FIBRILLATION
Primary results of the RE-LY trial (Randomized Evalua-
tion of Long-term anticoagulant therapy),7 presented at the
European Society of Cardiology 2009 Congress, highlighted
the superiority of dabigatran 150 mg over warfarin with re-
gard to prevention of stroke and systemic embolism in
18,113 patients with atrial fibrillation. In an important
follow-up analysis, the RE-LY investigators presented data
underscoring that the benefits of dabigatran relative to war-
farin were maintained even at sites in which the quality of
international normalized ratio control (assessed as time in
the therapeutic range) was excellent. These data add to the
evolving evidence base supporting dabigatran as a promisingThe Journal of Thoracic and Carnew alternative to warfarin for stroke prevention in atrial fi-
brillation. Given the reasonable safety profile for dabigatran
and the challenges of successfully maintaining an interna-
tional normalized ratio in the therapeutic range, dabigatran
may represent a major advance for anticoagulation of pa-
tients with atrial fibrillation.CORONARY REVASCULARIZATION IN PATIENT
WITH TYPE 2 DIABETES
The results of the BARI 2D trial (Bypass Angioplasty
Revascularization Investigation in Type 2 Diabetes) were pre-
sented inwhich 2368 patients with type 2 diabetes andmild or
stable cardiac symptoms were randomized to initial revascu-
larization with optimal medical therapy (with choice of revas-
cularization left to the treating physicians) versus initial
medical therapy alone. Overall, the results indicated that 5-
year mortality was no different between the initial revascular-
ization armversus initialmedical therapy (11.7% vs 12.1%;P
¼ .97), although by 5 years 42% of those patients randomized
to medical therapy had crossed over and undergone revascu-
larization. Likewise, there were no significant differences in
the rates ofmajor cardiovascular events between the 2groups.8
These results complement the findings of recent trials of opti-
mal medical therapy versus initial revascularization, such as
the COURAGE study (Clinical Outcomes Utilizing Revascu-
larization and Aggressive Drug Evaluation), for stable coro-
nary patients9 within a higher risk, diabetic population.ANTIPLATELET PHARMACOLOGY: THERAPIES
BEYOND CLOPIDOGREL
The 12-month results of the PLATO trial (PLATelet inhi-
bition and patient Outcomes in patients with acute coronary
syndromes) were presented by Dr P. Gabriel Steg (see
Wallentin and associates10), comparing the oral, reversible,
P2Y12 platelet antagonist, ticagrelor, to clopidogrel in over
18,000 patients being treated for acute coronary syndromes.
Ticagrelor provides a rapid onset of platelet inhibition and
is reversibly bound to platelets, resulting in functional recov-
ery of circulating platelets in approximately 48 hours. The
study found that ticagrelor provided a 16% reduction in the
risk of death from vascular causes, myocardial infarction, or
stroke by 12 months as compared with the clopidogrel group
(9.8% vs 11.7%; P< .001). This finding was evident by 30
days and sustained to 12 months. Major bleeding did not dif-
fer between the ticagrelor and clopidogrel treated groups, and
there was no significant differences in bleeding among the
4.5% of patients who underwent coronary artery bypass
grafting as part of the study.10 However, given the reversibil-
ity of the study drug, it is anticipated that platelet function
should return to baseline levels within 48 hours of treatment,
suggesting more rapid ability to perform bypass grafting for
those patients who require urgent surgical revascularization,
as compared with clopidogrel.diovascular Surgery c Volume 139, Number 4 1091
Meeting Proceedings Desai and ResnicTwo studies of the short-acting, intravenous P2Y12
platelet-inhibitor, cangrelor, were presented during the scien-
tific sessions. The CHAMPION PCI trial (Cangrelor versus
StandardTherapy toAchieveOptimalManagement of Platelet
Inhibition) randomized 8877 patients undergoing percutane-
ous coronary intervention (PCI) to receive either cangrelor
or clopidogrel before the PCI (with all patients receiving stan-
dard clopidogrel after the PCI procedure). The investigators
found no advantage for cangrelor, either in reducing ischemic
events or in the rates of post-procedural bleeding.11 The results
of the CHAMPION PLATFORM trial, which studied 5362
patients with acute coronary syndrome undergoing PCI and
randomized patients to receive cangrelor or placebo before
the procedure, with both populations treated with clopidogrel
after the PCI procedure, were similar. CHAMPION PLAT-
FORMfoundnosignificant reduction in the endpoint of death,
myocardial infarction, orurgent revascularization as compared
with placebo, although there was a reduction in the rates of
stent thrombosis in patients treated with pre-procedure
cangrelor as compared with placebo.12 The specific role for
cangrelor, if approved for use in the United States, remains
uncertain and requires further testing in subgroups of patients.
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